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Abstract
While sarcomas account for approximately 1% of malignant tumors of adults, they are particularly more common in children and
adolescents affected by cancer. In contrast to malignancies that occur in later stages of life, childhood tumors, including sarcoma, are
characterized by a striking paucity of somatic mutations. However, entity-defining fusion oncogenes acting as the main oncogenic
driver mutations are frequently found in pediatric bone and soft-tissue sarcomas such as Ewing sarcoma (EWSR1-FLI1), alveolar
rhabdomyosarcoma (PAX3/7-FOXO1), and synovial sarcoma (SS18-SSX1/2/4). Since strong oncogene-dependency has been dem-
onstrated in these entities, direct pharmacological targeting of these fusion oncogenes has been excessively attempted, thus far, with
limited success. Despite apparent challenges, our increasing understanding of the neomorphic features of these fusion oncogenes in
conjunction with rapid technological advances will likely enable the development of new strategies to therapeutically exploit these
neomorphic features and to ultimately turn the “undruggable” into first-line target structures. In this review, we provide a broad
overview of the current literature on targeting neomorphic features of fusion oncogenes found in Ewing sarcoma, alveolar rhabdo-
myosarcoma, and synovial sarcoma, and give a perspective for future developments.
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1 Introduction
Decades after the discovery of BCR-ABL1 t(9;22)(q34;q11) in
chronic myeloid leukemia [1, 2] and EWSR1-FLI1
t(22;11)(q24;12) in Ewing sarcoma (EwS) [3], more than
20,000 fusion genes have been identified in human malignan-
cies [4]. In cancer entities with high numbers of somatic mu-
tations, the vast majority of gene fusions are supposed passen-
ger mutations, i.e., byproducts of spontaneous genomic
rearrangements, which accumulate progressively over time
[5, 6]. However, in oligo-mutated childhood cancers, such as
EwS, fusion genes are acquired early in tumorigenesis either
through balanced chromosomal translocations [3] or through a
complex, but well-orchestrated, genomic rearrangement
called chromoplexy [7]. Once the respective fusion has oc-
curred, oligo-mutated cancer cells show a strong oncogene
addiction toward their disease-defining fusion oncogene
(e.g., EWSR1-FLI1 in EwS [3], PAX3/7-FOXO1 in alveolar
rhabdomyosarcoma (ARMS) [8, 9] and SS18-SSX1/2/4 in sy-
novial sarcoma (SS) [10–12]) in terms of tumor progression
and metastasis.
EwS is the second most common bone cancer in children
and was first described by James Ewing in 1921 [13]. It is
characterized by a small-round-blue cell phenotype and most-
ly arises in the metadiaphyseal bones of the lower extremities
and in the pelvic region [14]. While EwS is curable in local-
ized disease by radical surgery, radiotherapy, and chemother-
apy (5-year survival rate: around 83%), patients with dissem-
inated disease have dismal outcome (5-year survival rate: 37%
or less) [15]. Molecularly, EwS is defined by the fusion of the
EWSR1 gene and a transcription factor of the ETS-family, such
as EWSR1-FLI1 (85%) or EWSR1-ERG (10%) [14]. This
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fusion event rewires the affinity of the DNA-binding domain
of FLI1 and enables it to bind to GGAA-microsatellites
(GGAA-mSats) in addition to its physiological binding to
the ETS-specific DNA motif ACCGGAAGT. Interestingly,
the affinity to those mSats correlates strongly with an increas-
ing number of GGAA-repeats [16]. In turn, binding of
EWSR1-FLI1 to such GGAA-mSats converts them into de
novo enhancers and super-enhancers [16, 17]. Subsequently,
EWSR1-ETS fusion oncoproteins deregulate the gene expres-
sion of hundreds of genes, such asMYBL2 [18] and PPP1R1A
[19], which contribute to the malignant phenotype of EwS.
Notably, germline variants of GGAA-mSats that affect the
repeat length have recently been reported to contribute to
EwS susceptibility and tumor progression in EwS [18, 20].
Alveolar rhabdomyosarcoma (ARMS) is a subtype of rhab-
domyosarcoma that is believed to originate from precursor
cells in musculoskeletal tissue or mesenchymal stem cells
(MSCs) [21] and affects mostly children and adolescents
[22]. Histologically, ARMS resembles the architecture of lung
tissue by forming fibrovascular septa segregating the small,
often discohesive growing tumor cells in an alveoli-like pat-
tern [22]. Approximately two thirds of ARMS harbor a fusion
oncogene, whereas one third is fusion oncogene negative [23].
In fusion-positive ARMS, the FOXO1 transactivation domain
is fused to the DNA-binding domain of either PAX3 or PAX7
[8, 9]. In analogy to EwS, the generated fusion oncoprotein
binds a unique DNA motif (ACCGTGACTAATTNN for
PAX3-FOXO1) and hijacks this sequence as a de novo en-
hancer [24], which drives the expression of pro-tumorigenic
genes. While PAX3- and PAX7-FOXO1-positive ARMS have
the same prognosis in their localized states, PAX3-FOXO1-
positive tumors show a more aggressive phenotype once they
have metastasized [25].
Among fusion oncogene-driven sarcomas, SS is one of the
most prevalent ones accounting for approximately 7–8% of all
sarcomas [26]. Historically, SS has been believed to originate
from synovial cells due to its histopathological appearance
and its mostly joint-associated localization [27]. Although
the incidence of this tumor entity peaks at the age of 30 years,
30% of the patients are children or adolescents. On a molec-
ular level, SS is characterized by the SS18-SSX1, SSX2, or -
SSX4 fusion gene (hereafter collectively referred to as SS18-
SSX) [10–12]. These fusion proteins have been found to inter-
fere with normal BRG1-associated factor (BAF) complex (ali-
as SWI/SNF complex) formation by competing with wild-
type SS18, thereby causing concomitant loss of BAF47, a
tumor suppressive subunit of the BAF complex [28, 29].
Subsequently, the altered BAF complex binds broad
polycomb domains, opposes PRC-mediated repression of
gene sets, and activates transcription of a SS-specific gene
signature [29, 30]. Furthermore, it was shown that SS18-
SSX fusion proteins directly interact with the Wnt-
associated transcription factor family TCF/LEF and histone
deacetylases (HDACs) allowing Wnt-ligand independent
Wnt-activation in SS cells [31].
While the respective driver mutations in each of the entities
outlined above have long been identified, targeted therapies
exploiting (fusion) oncogene addiction in these tumors remain
to be integrated into standard of care treatment regimens. Given
the young age of disease onset, effective yet gentle alternatives to
mutilating surgeries and aggressive radio-chemotherapies are ur-
gently needed. In this article, we will review the current literature
on fusion oncogene specific therapeutic targets, evaluate their
clinical potential, and propose new strategies targeting oncogene
dependence in EwS, ARMS and SS.
2 Direct targeting of fusion oncogene DNA
2.1 CRISPR-CAS9-based strategies targeting
the breakpoint of fusion oncogenes and regulatory
elements bound by fusion oncoproteins
Gene engineering experiences a renaissance since the devel-
opment of the clustered regularly interspaced short palindrom-
ic repeats (CRISPR) associated protein 9 (CRISPR-CAS9)
technology. CRISPR-CAS9 has been successfully employed
in basic and preclinical research for the last couple of years
and faces its first phase I clinical trial at the moment [32, 33].
Besides monogenic disorders, malignant tumors driven by a
single-driver mutation represent favorable future indications
for the therapeutic use of CRISPR-CAS9 [34]. Among them,
tumors harboring a fusion oncogene constitute excellent can-
didates for oligonucleotide-based treatment strategies due to
the sequence specificity of their breakpoint region. Recently,
Chen et al. showed the efficacy of a CRISPR-CAS9-based
strategy inserting a suicide gene specifically into the
breakpoint region of two fusion oncogenes in prostate cancer
[35]. Similar strategies have been employed in fusion onco-
gene addicted sarcomas as well. Mitra et al. have recently
shown subtotal tumor clearance of subcutaneous EwS xeno-
grafts in mice treated with CD99-targeting nanoparticles car-
rying EWSR1-FLI1-specific sgRNA-RNPs [36]. In a human
myoblast model, the CRISPR-CAS9 mediated knockout of
PAX3-FOXO1 abrogated colony formation in vitro [37].
Another elegant strategy was pursued by Johnson et al., who
deleted the GGAA-mSat regulating the expression of NR0B1
using CRISPR-CAS9 and thereby impaired the proliferation
and oncogenic transformation of EwS cell lines [19].
Moreover, the advent of CRISPRi/a technology has enabled
researchers to silence or activate DNA regions, respectively, in
a highly specific way. Boulay et al. have employed this meth-
od to directly silence various GGAA-mSats and could abro-
gate tumor growth in vivo by targeting a SOX2-regulating
GGAA-mSat-enhancer using CRISPRi [38]. Taken together,
CRISPR-CAS9-based strategies represent novel, highly
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specific therapeutic approaches to hijack oncogene activity by
targeting either the fusion gene itself or its respective DNA-
binding motif.
2.2 Pharmacologic targeting the epigenetic
regulation of fusion oncogene expression
The concept of epigenetic regulation of gene expression and
its implications on health and disease, especially cancer, has
been widely accepted in the field of basic and translational
research [39, 40]. Epigenomic alterations are common in can-
cer and have become therapeutically accessible by the advent
of epigenome-modifying drugs such as HDAC inhibitors [39].
Although the functional principles of the fusion oncogenes in
the above-mentioned sarcoma entities have been studied ex-
tensively, their transcriptional regulation has not been fully
elucidated yet. However, in EwS, a strong dependence on
the presence of BRD4 (a member of the bromodomain and
extraterminal domain (BET) family) for efficient transcription
of EWSR1-FLI1 has been observed [41]. BRD4 is known to
bind acetylated lysine residues and promote transcription by
interaction with P-TEFb and RNA-polymerase II [42].
Notably, BET inhibition by JQ1 (+) impaired cell viability,
clonogenic, and migratory capacity and induced G1-
blockage [41]. In ARMS, Entinostat, an HDAC-inhibitor,
which has been found to reduce PAX3-FOXO1 expression
and induce subsequent chemotherapy sensitization in preclin-
ical models [43, 44], is currently being evaluated in combina-
tion with nivolumab in a phase I/II trial (INFORM2) [45] after
it was tolerated well in an earlier phase I study (ADVL1513)
[46]. As mentioned above, CRISPR-interference, a variant of
the CRISPR-CAS9 system that allows the selective silencing
of genes and intergenic regions, has been employed to silence
GGAA-mSats and thereby disrupt their enhancer capacity in
EwS cell lines [38]. This site-specific technology might rep-
resent a promising strategy to target fusion oncogenes them-
selves, not only their binding regions.
3 Direct targeting of fusion oncogene RNA
3.1 Targeting mRNA transcripts of fusion
oncoproteins using RNA interference (RNAi)
With the advent of the RNAi technique, knockdown of tran-
scripts including mRNAs of fusion oncogenes has become a
standard method to investigate their biological role in cell and
animalmodels. Due to their driver function in oncogenesis, direct
targeting of fusion oncogene transcripts has been the Holy Grail
of fusion-positive pediatric sarcoma treatment. Indeed, knock-
down of fusion oncoproteins in EwS [47, 48], ARMS [49, 50],
and SS [51, 52] consistently causes G0/G1 cell cycle arrest and
cell death in vitro, which supports the potential therapeutic
usefulness of this approach. Furthermore, it has been observed
that suppression of the fusion oncogene or direct downstream
target genes can facilitate differentiation of fusion-positive sarco-
ma cells in combinationwith adequate differentiation-stimulating
media in EwS [53], SS [29, 54], and ARMS [55]. Hence, differ-
entiation induction by RNAi and differentiation inducing drugs
(such as LSD1 and HDAC inhibitors [56, 57]) could be thera-
peutically implemented in pediatric sarcoma treatment regimens,
as exemplified by treatment of acute promyelocytic leukemia
with all-trans-retinoic acid [58].
Conversely, the therapeutic strategy of direct targeting of
fusion oncoprotein transcripts may also have some draw-
backs. Indeed, EwS cells in which EWSR1-FLI1 expression
was suppressed by RNAi showed higher metastatic potential
than those without EWSR1-FLI1 knockdown in vitro and
in vivo, which undermines the rationale for complete thera-
peutic suppression of fusion oncoprotein transcripts [59]. This
phenomenon, however, has been demonstrated, thus far, only
in EwS, whereas in SS and ARMS suppression of the respec-
tive fusion oncoprotein or their downstream target genes re-
duces invasion and migration in vitro [60–62].Moreover, high
expression of SLFN1, one of the EWSR1-FLI1 upregulated
genes, has been shown to be associated with higher sensitivity
to chemotherapeutics and superior patient survival [63], sug-
gesting the possibility that suppression of EWSR1-FLI1 may
lead to the emergence of chemo-resistant phenotype in EwS.
A major obstacle of implementing RNAi technique in the
clinic may reside in the difficulty of sufficiently and systemi-
cally introducing constructs into tumor cells. Incipient in vivo
studies using intratumoral application of siRNA demonstrated
certain anti-tumor effect in EwS [64, 65]. However, this ap-
proach requires frequent intratumoral injection or prior appli-
cation of siRNA, which is obviously not feasible in the clinical
setting. Development of nanoparticles or liposomes enabled
systemic application of siRNA in murine xenograft models
with mild anti-tumor effects, specifically promoting
cytostaticity rather than cytotoxicity, which may be attributed
to unsatisfactory suppression of fusion oncoproteins [66, 67].
A more specific approach with siRNA encapsulated into
transferrin-conjugated cyclodextrin-containing polycations
was tested in a murine metastatic EwS xenograft model, in
which the authors exploited the observation that cell-surface
transferrin receptors are highly expressed in the TC71 EwS
cell line [68]. This study underlines the importance of tumor-
specific delivery strategies for efficient RNAi-based therapeu-
tic approaches. Recent advances in understanding exosome
functioning and engineering of recombinant exosomes could
overcome current limitations by increasing siRNA delivery
efficacy [69].
Taken together, we believe that there is still ample room to
investigate potential applications of directly targeting fusion
oncoprotein transcripts in sarcomas via RNAi techniques,
which could be facilitated by developing more specific
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delivery systems and utilizing combinatorial approaches with
other therapeutic modalities.
3.2 Targeting the splicing machinery involved
in post-transcriptional modification of fusion
oncoproteins
The first association of post-transcriptional modifications of
transcripts with fusion oncoproteins was identified through
investigations on EWSR1-FLI1 function [70]. EWSR1-FLI1
was found to modulate the splicing machinery by interacting
with RNA polymerase II [71], non-fused (wild type) EWSR1
[72], and YB1 [73], creating atypical mRNA isoforms.
Selvanathan et al. gave an overview for potential isoforms
alternatively spliced by EWSR1-FLI1 [74]. Since isoform var-
iations could be a distinct feature of tumor cells, tumor-
specific isoform signatures could be therapeutically
implemented.
Increased VEGF165/VEGF189 ratio by alternative splic-
ing has been reported to be caused by EWSR1-FLI1 inhibition
of CAPER-alpha (RBM39) [75], which confers a more
neoangiogenic phenotype to EwS by recruiting bone
marrow-derived progenitor cells in a murine xenograft model
[76]. Moreover, selective intratumoral suppression of
VEGF165 expression by RNAi significantly reduced tumor
growth in vivo [77]. Although specific protein isoforms might
represent druggable targets using isoform-specific antibodies,
the clinical relevance of this observation remains unclear.
Wild-type EWSR1 has been shown to alternatively splice
the transmembrane domain coding exon of FAS/CD95 recep-
tor [78]. In EwS, EWSR1-FLI1 interferes with alternative
splicing of FAS/CD95 by direct interaction with non-fused
(wild-type) EWSR1, resulting in exon 6 exclusion and pro-
duction of a soluble isoform, which exhibits lower FAS-
mediated apoptosis compared to the transmembrane form
[78]. This observation may imply that suppression of
EWSR1-FLI1 by RNAi could promote a shift toward a
FAS-mediated apoptotic phenotype.
Moreover, EWSR1-FLI1 reduces the elongation speed of
RNA polymerase II on CCND1 leading to preferential alter-
native splicing of the D1b isoform, which has a higher onco-
genic potential than the D1a isoform [79]. Thus, suppression
of EWSR1-FLI1 may lower the D1b/D1a ratio, which could
sensitize EwS cells toward CDK4/6 inhibitors.
One of the subunits of the chromatin remodeling BAF
complex, ARID1A, has been recently shown to be a splicing
target of EWSR1-FLI1 [80]. ARID1A-L generated by alter-
native splicing in EwS cells plays an important role in tumor
growth and promotes the stability of EWSR1-FLI1. Although
this observation clearly demonstrated that complex mecha-
nisms of (alterative) splicing are operative in EwS, it remains
to be illuminated if and how they can be addressed
therapeutically.
Evidence indicating a direct association of fusion oncoproteins
with alternative splicing in SS and ARMS is still missing.
However, the ribonucleoprotein SYT-interacting protein/co-
activator activator (SIP/CoAA), which functions as a RNA splic-
ing modulator, was found to bind to the SS18-SSX2 fusion
oncoprotein, implying a potential role of SS18-SSX in alternative
splicing in SS [81]. Although comprehensive data demonstrating
potential tumor-specific isoform variations created by fusion
oncoproteins is still missing, recent advances in transcriptome
analysis may uncover tumor-specific isoform signatures, which
could be further exploited to identify potential oncogenic “iso-
form-addiction”. In turn, researchers may be able to take a new
approach in revealing potential therapeutic targets in terms of tu-
mor vulnerability caused by isoform-addiction.
4 Direct targeting of fusion oncoproteins
4.1 Targeting post-translational modification, protein
folding, and degradation of fusion oncoproteins
Post-translational modifications, such as phosphorylation,
acetylation, or ubiquitination, are a key aspect of the regula-
tion of protein function. These modifications can allow or
inhibit the activity of a protein by changing its structure, in-
ducing intracellular redistribution, or marking the protein for
degradation [82]. In the case of the above-mentioned fusion
oncoproteins, pharmacological alteration of their post-
translational modifications is an interesting strategy to thera-
peutically influence these oncoproteins, as they are difficult to
target directly.
In ARMS, phosphorylation of PAX3-FOXO1 at multi-
ple sites has been shown to be important for stability of the
fusion oncoprotein and its transcriptional activity [83]. In
accordance with this, the multikinase inhibitor PKC412
has been reported to reduce the phosphorylation of certain
sites at the PAX3 domain, to decrease the transcriptional
activity of PAX3-FOXO1, and to exert an anti-tumorigenic
effect in vitro and in xenograft models [83, 84]. As a more
specific example, Polo-like kinase 1 (PLK1), a serine/
threonine kinase, also phosphorylates and stabilizes the
fusion protein [85]. In contrast, the authors could demon-
strate that phosphorylation of wild-type FOXO1 at the
equivalent serine residue triggers nuclear export of the
transcription factor [85]. Inhibition of PLK1 with the small
molecule BI 2536 causes increased proteasomal degrada-
tion of PAX3-FOXO1 and tumor regression in a xenograft
mouse model, an effect that could be reproduced in a dif-
ferent study using the PLK1 inhibitor Volasertib [85, 86].
Furthermore, multiple studies have shown PAX3-FOXO1
to be a substrate of GSK3β, inhibition of which reduces
transcriptional activity of the fusion protein and prolifera-
tion of tumor cells in a PAX3-FOXO1 dependent manner
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[87, 88]. Additionally, PAX3-FOXO1 is phosphorylated
by cyclin-dependent kinase 4 (CDK4) in the ARMS cell
line RH30 and inhibition of CDK4 by facsaplysin reduces
the transcriptional activity and increases its cytoplasmatic
levels, indicating redistribution [89]. In contrast, evidence
has been published that phosphorylation of PAX3-FOXO1
by AKT reduces transcription of PAX3-FOXO1 target
genes [90]. Concordantly, indirect activation of AKT via
the SERCA inhibitor thapsigargin has been shown to re-
duce binding of PAX3-FOXO1 to regulatory DNA ele-
ments and to reduce proliferation in vitro and in vivo [91].
EWSR1-FLI1, the most common fusion oncoprotein in EwS,
has also been found to be subject to various post-translational
modifications. Evidence of phosphorylation of EWSR1-FLI1
was first gathered in 2001 by Olsen and Hinrichs, who identified
a PKC phosphorylation site and reported this phosphorylation to
be essential for transcriptional function of the oncoprotein [92].
Interestingly, PKC-β has been recognized to be necessary for
EwS growth in xenograft experiments and a decrease in
PKC-β activity might be a factor responsible for the reduced
DNA-binding and transcriptional activity of EWSR1-FLI1 and
the cytotoxic effect observed after treatment with Englerin A [93,
94]. Additionally, a different site of EWSR1-FLI1 has been
shown to be a target of MAPK/ERK and JNK (c-Jun N-
terminal kinase) after DNA damage but the functional and po-
tential therapeutic relevance of these phosphorylations remains to
be elucidated [95]. Similarly, evidence of acetylation, methyla-
tion by PRMT1/PRMT8, and O-GlcNAcylation of EWSR1-
FLI1 has been reported with yet mostly unclear functional and
therapeutic implications [96–99]. Recently, Gierisch et al. identi-
fied EWSR1-FLI1 to be subject to ubiquitination and subsequent
proteasomal degradation [100]. Furthermore, they recently dem-
onstrated that the ubiquitin-specific protease 19 (USP19)
deubiquitinates the fusion oncoprotein [101]. Depletion of
USP19 was shown to decrease EWSR1-FLI1 expression levels,
but neither the expression of wild-type of EWSR1 nor FLI1, and
to reduce tumor growth in vitro and in vivo indicating a potential
therapeutic value for USP19 inhibition [101]. In addition to that,
EWSR1-FLI1 has been reported to be a substrate of the chaper-
one HSP90 and inhibition of HSP90 by the small molecule PU-
H71 reduced tumor cell growth in vitro and tumor burden in
xenograft experiments [102]. On a similar note, it has been
shown that reduced levels of EWSR1-FLI1 can also be achieved
by treatment with theHDAC1/3 inhibitor Entinostat, as HDAC1/
3 deacetylates HSP90 and thereby increases its activity [103].
Even though the fusion oncoprotein in SS was identified over
25 years ago and there are multiple sites of post-translational
modification present in the domains of wild-type SS18 and
SSX1/2/4, little has been published about the impact of post-
translational modifications on SS18-SSX and their therapeutic
value [10, 11]. Nevertheless, Patel et al. have recently shown that
SS18-SSX is ubiquitinated and thereby marked for degradation
by the MCL-1 ubiquitin ligase E3 (MULE) at the lysine K23 of
SS18, which is not a known ubiquitination site inwild-type SS18
[104]. Furthermore, they showed that MULE is a substrate of the
E3 ubiquitin-ligase MDM2, which is only active in its
deacetylated state that is ensured by the histone deacetylase 2
(HDAC2) [104–106]. As a reduced activity of HDAC2 thus
leads to increased ubiquitination and degradation of SS18-SSX,
this might be an additional mechanism responsible for the cyto-
toxic effect of HDAC inhibition in SS cells [107].
4.2 Targeting fusion oncoprotein-specific
neoantigens by immunotherapy
The successful clinical implementation of checkpoint inhibi-
tors and CAR-Tcells in the routine treatment of various tumor
entities has heralded a new era of immunotherapies in cancer
[108, 109]. Tumor-specific neoantigens derived from fusion
oncogene breakpoint regions have attracted great scientific
interest for many years, especially as an alternative to single-
nucleotide variant-derived tumor-specific antigens [110].
Recently, gene-fusion-derived neoantigens were found to in-
duce tumor-specific Tcells and facilitated a complete response
in a head and neck-cancer patient treated with immune check-
point inhibitors despite an overall low tumor mutational bur-
den [111]. Hence, fusion oncogene-driven pediatric sarcomas
might represent promising candidates for immunotherapies
targeting breakpoint-derived neoantigens.
Indeed, breakpoint-specific neoantigens have been predict-
ed and in part validated for EWSR1-FLI1 [112], PAX3-
FOXO1 [112], and SS18-SSX1 [113]. For EWSR1-FLI1, it
was shown that a modified 9-mer peptide of the fusion site
(YLNPSVDS) was able to induce a robust immune response
in vitro and in vivo facilitating prolonged survival of
xenograft-bearing mice after treatment with YLNPSVDS-
specific cytotoxic T lymphocytes (CTLs) [114]. This is of
special interest, since native peptides of the breakpoint region
have failed to provoke significant CD8+ CTL responses be-
fore and show weak MHC-binding affinities [114, 115].
Moreover, fusion-restricted immune responses seem to highly
depend on the HLA alleles. For instance, two highly similar
peptides of the PAX3-FOXO1 breakpoint region showed
strikingly different results depending on the HLA alleles used
in the respective study: The RS10 peptide (SPQNSIRHNL)
was able to induce highly effective CTLs in HLA-B7+ donor
peripheral blood mononuclear cells and allowed killing of
HLA-B7+ ARMS cells [116]. In contrast, the modified 9-
mer peptide GLSPQNSIK, which shares 6 amino acids with
RS10 and was optimized for HLA binding, failed to induce a
potent CTL response in HLA-A3+ CD8+ T cells [117].
Targeting neoantigens derived from the breakpoint region of
fusion oncogenes represents a sophisticated, yet challenging
approach. The development of CAR-T cells specific for the
peptide-MHC-complex might represent a promising strategy
to tackle the low antigenicity of fusion peptides in the future.
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5 Indirect targeting of fusion oncoproteins
and their function
5.1 Targeting protein-protein interactions of fusion
oncoproteins
Fusion oncogenes and their function have been extensively
characterized over the past decades. By now, it has been well
accepted that fusion oncogenes orchestrate a tumorigenic re-
programming comprised of a plethora of interaction partners
rather than acting in isolated systems. This holds especially
true for SS18-SSX oncoproteins that exert their deleterious
effects by interacting with the BAF complex, a multimember
epigenetic regulatory machinery [29]. Such interaction part-
ners might represent druggable targets that could indirectly
compromise fusion oncoprotein functioning.
Apart from their direct DNA-binding capability, EWSR1-
FLI1 and PAX3-FOXO1 also act through direct protein-
protein interactions. For instance, it has been shown that
EWSR1-FLI1, but not wild-type EWSR1, directly binds
RNA helicase A [118] and reduces helicase activity [119].
RNA helicase A is involved in many cellular processes such
as re-organizing RNA secondary structures, spliceosome as-
sembly, and initiation of translation. In turn, blocking this
interaction using the compound YK-4-279 translated in in-
creased apoptosis and reduced growth of EwS orthotopic xe-
nografts and might represent an elegant strategy to target this
neomorphic feature of the fusion oncogene [120]. Moreover,
Li et al. found a direct link between p53 inhibition and
EWSR1-FLI1 [121]. Mutations in p53 have been found in
as little as 5–7% of EwS [14]; however, even in wild-type
sarcomas, p53 function seems to be compromised in analogy
to other fusion-positive malignancies such as fusion-driven
leukemia [121–123]. In EwS, the N-terminal domain of
EWSR1-FLI1 was identified to form a complex with
HDAC1 and p53 leading to subsequent deacetylation of p53
and inhibition of its downstream signaling [124]. However, it
remains unclear whether this interaction is indeed a
neomorphic feature of the fusion oncogene and not intrinsic
to wild-type EWSR1, especially since the interaction seems to
involve the N-terminal region of EWSR1-FLI1 [121, 124].
As outlined before, a recent study revealed a direct interaction
of EWSR1-FLI1 with the BAF complex via its subunit
ARID1A [80]. The authors could show that ARID1Awas dif-
ferentially spliced and accumulated in its long isoformARID1A-
L in the presence of EWSR1-FLI1. Notably,modulation ofwild-
type EWSR1 levels did not affect the isoform switch, pointing
toward a neomorphic feature of the fusion gene [80]. ARID1A-L
was shown to stabilize EWSR1-FLI1 and bolstered its oncogen-
ic capacity. Interestingly, the above-mentioned compound YK-
4-279 also blocked this interaction and prevented binding of
EWSR1-FLI1 to the BAF complex via ARID1A. Hence,
TK216, a slightly improved version of YK-4-279 that has been
approved for a phase I clinical trial in relapsed or refractory EwS,
represents a very promising candidate for future targeted thera-
pies of this devastating disease [125].
Lastly, Embree et al. could demonstrate the interaction of
EWSR1-FLI1 with wild-type EWSR1 in a zebrafish model
and in human cell lines [72]. The researchers observed mitotic
defects in EWSR1-FLI1 expressing zebrafish embryos and
HeLa cells. Since the observed phenotype closely resembled
one that was observed in EWSR1-deficient embryos, a direct
interaction of EWSR1-FLI1 with EWSR1 was suspected.
Indeed, it was found that the fusion oncoprotein bound wild-
type EWSR1 and inhibited its function resulting in spindle
malformation and mis-localization of Aurora kinase B [72].
Anyhow, the authors did not expand on how these findings
might translate into therapeutic consequences and the effects
of targeting EWSR1 in EwS still remain to be investigated.
Apart from EWSR1-FLI1, PAX3-FOXO1 functioning has
also been found to rely on direct interactions with other pro-
teins, especially kinases, as reviewed above [85–91].
Although all of the phosphorylation sites also exist in wild-
type PAX3 or FOXO1, respectively, and thereby do not rep-
resent neomorphic features of the fusion oncogene per se,
kinase inhibitors showed different effects on the fusion onco-
gene than on wild-type PAX3 and FOXO1 [85]. Moreover,
some of them directly interfered with its binding to the
neomorphic binding site ACCGTGACTAATTNN that is
enriched in PAX3-FOXO1 associated super-enhancers [91].
Hence, kinase inhibitors do not particularly exploit
neomorphic features rather than inhibiting neomorphic func-
tioning of PAX3-FOXO1.
In SS, the interactions of its fusion oncoprotein with the
BAF complex have been widely studied and are reviewed
below. Besides subunits of the BAF complex, only a few other
proteins have been demonstrated to bind SS18-SSX fusion
proteins directly. For instance, SS18-SSX1 was found to sta-
bilize HDM2, a negative regulator of p53 that consecutively
promoted p53 ubiquitination and degradation resulting in re-
sistance to apoptosis-inducing drugs [126].
To conclude, targeting proteins that directly interact with
fusion oncoproteins might constitute a useful addition to well-
established therapies or novel treatment strategies directed
against the fusion oncoprotein itself. Yet, the lower specificity
of such approaches and the resulting side effects might con-
stitute an obstacle for future clinical trials.
5.2 Targeting protein-DNA interactions of fusion
oncoproteins including epigenetic rewiring
and subcellular localization
While EWSR1-FLI1 and PAX3-FOXO1 are aberrant tran-
scription factors directly binding to specific DNA sequences,
SS18-SSX instead interacts with chromatin remodeling com-
plexes [14, 22, 28, 30, 127]. Therefore, the oncogenicity of
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these oncoproteins is rooted in their influence on the state of
chromatin and on the expression of certain genes. Preventing
these oncoproteins to access the DNA might consequently be
a promising strategy for more specific therapies of these
sarcomas.
As an example, the small molecule lurbinectedin and
trabectedin have been found to induce a nucleolar redistribu-
tion of EWSR1-FLI1 in EwS cells leading to an increase in
heterochromatin-associated histone methylations at EWSR1-
FLI1 target genes [128, 129]. Both compounds have preclin-
ically shown efficacy against EwS cells, especially in combi-
nation with other compounds such as irinotecan or olaparib
[128, 130]. Lurbinectedin also has shown a good safety profile
and anti-cancer activity as a single agent in a phase II clinical
trial [131].
As fusion-driven sarcomas are characterized by the paucity
of other genetic mutations and due to the functions of their
disease-defining oncogenes, epigenetic dysregulation plays an
important role in the maintenance of their phenotype. Hence,
epigenetic modulators, which are increasingly becoming of
interest in other malignancies as well, are major potential tar-
gets in EwS, SS and ARMS.
One group of epigenetic regulators are HDACs, which re-
move acetyl groups from lysine residues of histone chains and
thereby regulate gene expression [132]. Indeed, in preclinical
models of EwS, HDAC inhibitors have been shown to induce
apoptosis, promote differentiation, and reduce tumor growth
in xenograft experiments [57, 133]. Antitumorigenic activity
of HDAC inhibitors has also been reported in preclinical
models of SS and ARMS [134–138]. Unfortunately, the few
clinical trials that have been conducted to investigate the effi-
cacy of HDAC inhibition have shown onlymodest response at
best in these entities, when used as single agents [139–143].
HDAC inhibitors might therefore be of greater use in combi-
nation with other anti-cancer drugs. Apart from standard che-
motherapeutics, possible combination partners might also in-
clude additional epigenetic drugs. Using the single agent
SP2509, reversible inhibition of lysine-specific demethylase
1 (LSD1), a subunit of the Mi-2/nucleosome remodeling and
deacetylase (NuRD) complex, induces apoptosis and reduces
xenograft tumor growth in EwS [144]. Interestingly, this
LSD1 inhibitor has a synergistic effect with the HDAC inhib-
itors suberoylanilide hydroxamic acid (SAHA) or romidepsin
in vivo [145, 146]. Based on these preclinical studies, more
investigations focusing on this and other combinations with
HDAC inhibitors are justified.
Another interesting epigenetic modulator is the enhancer of
zeste homolog 2 (EZH2), a Polycomb-group protein involved
in DNA methylation [147]. Knockdown or pharmacological
inhibition of EZH2 in ARMS cells leads to apoptosis and
reduced tumor growth of ARMS xenografts in vivo [148]. In
EwS, the EZH2 promoter is a direct target of EWSR1-FLI1.
Here, RNAi mediated downregulation of EZH2 inhibits
clonogenicity in vitro and suppresses tumor development
and metastasis in xenograft experiments [149]. However, a
tumor xenograft study using 4 different cell lines of ARMS
and EwS showed only limited anti-tumor activity of the EZH2
inhibitor tazemetostat for both entities [150]. Therefore, fur-
ther preclinical and clinical investigation into the use of EZH2
inhibitors for treatment of ARMS and EwS is of need. In SS
cells, inhibition of EZH2 with the small molecule EPZ005687
has been shown to impair proliferation and migration [151].
However, in a phase II clinical trial of tazemetostat as a single
agent in patients with SS, stable disease could be achieved in
only 33% of treated patients indicating the possible necessity
of combination partners [152].
Yet, another group of proteins involved in chromatin regu-
lation is the bromodomain and extra terminal domain (BET)
family. Its members, such as BRD4, are able to recognize and
bind acetylated histones with their bromodomains and play a
role in epigenetic memory and transcription regulation [153].
With the advent of specific BET bromodomain inhibitors
(JQ1 and iBET) bromodomain containing proteins have en-
tered the spotlight as attractive potential targets for a variety of
different cancer entities [154, 155]. In EwS cells, BRD4 has
been found to form a transcriptional complex with EWSR1-
FLI1 and -ERG. RNAimediated knockdown or JQ1mediated
inhibition of BRD4 resulted in significantly impaired onco-
genic phenotype and reduced xenograft tumor growth [156].
ARMS cells have also been reported to be sensitive to JQ1 in
preclinical models [157]. In addition to that, Gryder et al.
could explain this sensitivity mechanistically by showing that
PAX3-FOXO1 function relies on BRD4 recruitment at de-
fined super-enhancers [24]. Furthermore, it was recently dem-
onstrated that BRD9 is a component of the SS18-SSX con-
taining BAF complexes in SS [158]. Inhibition or targeted
degradation of BRD9 induced downregulation of oncogenic
programs and reduced growth of SS xenografts [158]. In the
light of these preclinical results, clinical trials to investigate
the efficacy of BET inhibitors for the treatment of fusion-
driven sarcomas as single agents or in combinations seem to
be warranted.
5.3 Targeting specific downstream pathways
of fusion oncoproteins
Malignant transformation and maintenance of tumorigenesis
in EwS, SS, and ARMS depend on the expression of their
specific fusion proteins to the extent that their deletion results
in cell death. However, there are no available drugs that can
directly target these fusion proteins, so far. Since the expres-
sion of these fusion proteins also completely rewires the ex-
pression and regulation of pathways and downstream effec-
tors, there is great potential for alternative targeted therapeutic
interventions. This section will cover a range of targeted
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therapies described to date against commonly altered onco-
genic pathways in these fusion-driven sarcomas.
5.3.1 Insulin-like growth factor receptor (IGF-1R) pathway
Tumorigenesis in translocation-driven tumors is critically me-
diated via the IGF-1R signaling pathway [159]. Preclinical
EwS models show a constant activation of the IGF-1R-
mediated signaling pathway [160], which promotes drug es-
cape [161] and seems to be essential for EwS cell viability
[162]. In SS, the translocation induces the expression of IGF2,
which is also required for tumor growth in vivo [163], while its
immune targeting inhibits tumor growth and metastasis for-
mation in ARMS [164]. Additionally, IGF-1R inhibition in-
duces apoptosis of SS cells in vitro [165]. At the same time,
IGF-1R is a direct target of the PAX3-FOXO1 fusion in
ARMS [166].
Several antibodies and small molecules against IGF-1R
pathway have been tested in clinical trials including phase II
and III. However, the results have only been moderate so far
due to acquired resistance through different mechanisms
[167–169]. Yet, given the outstanding preclinical results ob-
tained when blocking this pathway, significant efforts are be-
ing made to develop combined therapies that could overcome
these hurdles. For instance, a recent report suggests combining
heparanase inhibitors with IGF-1R antagonists for treatment
of metastatic SS [170], and a combined therapy including
BET inhibitors has been set forth for EwS [171]. In the case
of ARMS, it has been proposed that the simultaneous inhibi-
tion of IGF-1R and additional tyrosine kinases could help to
overcome resistance to treatment. For instance, concomitant
inhibition of IGF-1R and YES/SRC family tyrosine kinase
[172], a combination of an anti-IGF-1R antibody and the in-
hibition of the anaplastic lymphoma kinase (ALK) [173], or
treatment with Ceritinib (ALK and IGF-1R inhibitor) with the
multikinase inhibitor sorafenib have been suggested based on
preclinical results [174].
5.3.2 Mitogen-activated protein kinase pathway
Tyrosine kinases are highly expressed in sarcomas including
EGFR and PDGFRA in SS, FGFR, and EGFR in ARMS, and
upstream mediators of ERK1/2 in EwS [175, 176]. Indeed,
ERK1/2 is activated in the majority of EwS cell lines and is
thought to hold a pivotal role in tumor development [177]. In
fact, the A673 EwS cell has a constitutively activating mutation
in BRAF [178]. Accordingly, the inhibition of ERK1/2 precursor
MEK1/2 using U0126 impedes migration and invasion of EwS
cell lines [177]. Besides, pharmacological treatment with FGFR
inhibitor PD-173074 yielded a decrease in tumorigenic features
in preclinical studies [179]. Therefore, mitogen-activated protein
kinase (MAPK) pathway blocking agents such as RAF inhibitors
have entered clinical trials [180].
In SS, the situation is partially different: although
ERK1/2 MAPK signaling pathway components have been
proposed as targets of SS18-SSX, few reports describing
their role and druggability in SS are available so far [181,
182]. However, there is a targetable upregulation of EGFR,
PDGFRA, and PDGFRB in SS that can be exploited thera-
peutically by using specific small molecule inhibitors [183,
184]. Additionally, and similarly to EwS, FGFR2 is also
being studied as a potential therapeutic target in SS [185].
Finally, it has been recently shown that nintedanib, a triple
kinase inhibitor targeting PDGFR, VEGFR, and FGFR path-
ways, presents promising effects in a preclinical study for SS
that are beyond those shown by imatinib [186]. In ARMS,
the upregulation of EGFR presents a rationale for the use of
anti-EGFR monoclonal antibodies such as cetuximab that
has proven to be effective in preclinical studies [187].
Notably, due to the high expression of FGFR4, the inhibitor
PD-173074 has shown similar preclinical promising effects
in ARMS as in EwS [176]. Moreover, sorafenib, a
PDGFRA and RAF inhibitor, reduced tumor growth in a
mouse model for ARMS [188].
5.3.3 Sonic hedgehog (SHH) pathway
In ARMS, the expression of sonic hedgehog pathway effec-
tors like GLI1/2 is altered [189]. Inhibitory targeting of
GLI1/2 using GANT-61 leads to a blockage of tumor growth
in vivo, and its effect was shown to be synergistic with com-
monly used chemotherapeutic drugs for ARMS such as
temsirolimus or vincristine [190]. Similarly, a decrease in cell
viability and induced cell death was obtained in vitro by treat-
ment with arsenic trioxide (ATO), a different GLI1 inhibitor
[191], and in vivo by treatment with the sonic hedgehog path-
way inhibitor foskolin [192]. Additionally, apoptosis-inducing
agents like betulinic acid have been demonstrated to impair
tumor growth in preclinical studies via inhibition of the hedge-
hog pathway in ARMS [193]. Finally, in order to avoid escape
mechanisms, targeted therapies including GANT61 and the
dual PI3K/mTOR inhibitor PI103 have shown a synergistic
effect on ARMS cells apoptosis [194].
GLI1 was also shown to be upregulated in EwS and driven
by the translocation [195], and therefore, therapeutic ap-
proaches using ATO have been attempted with promising pre-
clinical results [196]. Thus, ATO was included in the Pediatric
Preclinical Testing Program (PPTP) [197] where it unfortu-
nately yielded negative results.
In the case of SS, since GLI and SMO were found to be
overexpressed in patient’s tumors [198] and since Notch has
been shown to activate GLI1, a Notch inhibitor in combina-
tion with vismodegib was tested in phase II trial that accepted
SS patients to be enrolled (NCT01154452). Unfortunately, the
inhibitor was discontinued and the trial had to be prematurely
ended.
Cancer Metastasis Rev (2019) 38:625–642632
5.3.4 Wnt/β-catenin pathway
The Wnt pathway is activated in most SS [199, 200] and this
activation is mediated by SS18-SSX [201]. Following this ratio-
nale, Wnt inhibitors such as pyrvinium have been preclinically
tested with promising results [202]. Beyond blocking the path-
ways using SS18-SSX-directed small molecules, targeting some
of its interacting proteins has been attempted. For instance,
desatinib-a YES1 tyrosine kinase inhibitor-has been demonstrat-
ed to block the Wnt pathway leading to impairment of cell pro-
liferation in SS [203]. Additionally, SS patients have been en-
rolled in a results-pending trial to test an antibody against theWnt
receptor FZD10 (NCT01469975).
In contrast, the relevance and potential for clinical interven-
tion in the Wnt pathway in ARMS remains highly controver-
sial [204]. So far, a single study by Annavarapu et al. found an
inhibition of proliferation and self-renewal capacity after phar-
macological re-activation of the Wnt pathway in vitro [205].
Interestingly, in EwS, even though Wnt activation is con-
sistent with worse clinical outcomes and a more aggressive
phenotype in vitro, cell populations present a highly heteroge-
neous activation of the Wnt signaling pathway, which could
be at least partially mediated by the inhibition of EWSR1-ETS
protein functions [206]. So far, WNT974-a modulator of the
Wnt pathway at PORCN level-showed a significant delay in
formation of metastasis in vivo [207].
All in all, combined targeting of oncogenic fusion proteins
along with specific pharmacological intervention of one or
multiple deregulated pathways may constitute a promising
therapeutic approach to overcome drug resistance for these
fusion-driven malignancies.
6 Conclusions and perspectives
Reviewing the current literature on neomorphic features of fusion
oncoproteins in EwS, ARMS, and SS, we have presented four
modalities of targeting fusion oncogenes in these devastating
childhood sarcomas (Figure 1). First, oncogene DNA or their
respective binding sites can be directly targeted by gene editing
strategies, such as CRISPR-CAS9 or CRISPRi. Second, onco-
gene mRNA transcripts represent a favorable target for RNAi-
based therapeutic approaches. Moreover, fusion oncoproteins
that interfere with the splicing machinery allow isoform-
specific treatment strategies. Third, oncoproteins and their sub-
cellular localization can be directly targeted either by inhibiting
or inducing their post-translational modification, respectively.
Additionally, breakpoint regions constitute excellent targets for
immunotherapies once they are sufficiently presented by the tu-
mor cells. Fourth, unique interactions of fusion proteinswith their
respective interaction partners have already been successfully
exploited in clinical trials (e.g., using YK-4-279). Furthermore,
due to the lack of somatic mutations and the importance of epi-
genetic alterations for the malignant phenotype of fusion-driven
sarcomas, targeting epigenetic regulators has been found to be
promising in these entities. In a more system-based manner,
Fig. 1 Scheme depicting the different targeting strategies of fusion oncogenes in pediatric fusion-driven sarcomas. Fusion oncogenes can be targeted on
their DNA level (1), RNA level (2), protein level (3), and by targeting downstream functions and interaction partners (4).
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tackling downstream pathways and regulatory networks of fu-
sion oncogenes might add to the arsenal of indirect treatment
options in EwS, ARMS and SS.
Taken together, neomorphic features of EWSR1-FLI1,
PAX3/7-FOXO1, and SS18-SSX fusion proteins have been
therapeutically addressed in the past and represent a potent,
highly specific approach worthy of further investigations in
the future. New delivery strategies, advances in understanding
and exploiting tumor immunity, new drugs targeting fusion
oncoproteins, epigenetic regulators, and interaction partners
might help to overcome the hurdles that have proved these
oncogenes to be notoriously difficult to target.
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